Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Health

Champignon Brands appoints Jim Bailey, former president of Red Bull Canada, to its special advisory committee

He will champion the company’s Novoformulations-branded delivery systems for the pharmaceutical, nutraceutical and psychedelic medicine industries

Champignon Brands Inc (CSE:SHRM) (OTCMKTS:SHRMF) has appointed Jim Bailey, the former president of Red Bull Canada, to its special advisory committee.

Vancouver-based Champignon said Bailey will champion the marketing, distribution and commercialization of the company’s Novoformulations-branded novel delivery systems for the pharmaceutical, nutraceutical and psychedelic medicine industries.

The group noted that Bailey also previously served as the global chief marketing officer for Merrell Outdoors, overseeing both product and consumer marketing with annual revenues of US$600 million.

Prior to his tenure at Merrell, Bailey served as president of Red Bull Canada, playing an instrumental role in launching the Red Bull brand in Canada and growing the business to $150 million in annual revenue with over 300 employees nationwide.

READ: Champignon Brands inks blockbuster deal to roll out network of psychedelic medicine clinics in North America

“I am very excited to be part of a company that is leading the way in finding alternative solutions to traditional pharmaceuticals with science-based research and functional products,” Bailey said in a statement Thursday.

“My background in heavily regulated industries coupled with my experience in the CPG space provides a great compliment to an already talented and experienced advisory board.”

Novoformulations, a 100%-owned subsidiary of Champignon, is presently working with ketamine, anaesthetics and adaptogenics, as well as a host of pharmaceuticals and natural molecules at a purpose-built good manufacturing practice (GMP) and pharmaceutical (DIN) licensed facility in Quebec.

Champignon said the subsidiary is actively formulating, developing and working to commercialize bioavailable delivery platforms, including transdermal (topical), intranasal and sublingual.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK